{"id":982324,"date":"2026-07-16T09:33:22","date_gmt":"2026-07-16T13:33:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/"},"modified":"2026-07-16T09:33:22","modified_gmt":"2026-07-16T13:33:22","slug":"clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/","title":{"rendered":"Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI"},"content":{"rendered":"
\n

\n Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) — <\/strong> Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering non\u2011hallucinogenic neuroplastogen\u2011derived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, announced today compelling ex vivo mucoadhesion results for its intranasal formulation of MEAI (5\u2011Methoxy\u20112\u2011aminoindane). Leveraging a nasal drug\u2011delivery system, the new formulation demonstrated markedly improved nasal residence characteristics compared with a standard MEAI solution.<\/p>\n

Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential. These results reinforce Clearmind\u2019s strategy of developing differentiated, next\u2011generation treatments for AUD and other high\u2011need indications.<\/p>\n

The study forms a core component of Clearmind\u2019s intranasal MEAI development program, designed to overcome the limitations of rapid mucociliary clearance and deliver more consistent, effective dosing.<\/p>\n

The study was conducted as part of Clearmind\u2019s development program focused on the development of an intranasal formulation of MEAI for the treatment of AUD. A key objective of the program is to improve the residence time of MEAI within the nasal cavity, potentially increasing the opportunity for absorption before mucociliary clearance removes the formulation from the nasal surface.<\/p>\n

\n Ex Vivo Nasal Residence Time Evaluation<\/b>\n <\/p>\n

The ex vivo mucoadhesion study was designed to evaluate the ability of its intranasal MEAI formulation to remain associated with nasal tissue over time compared with a non\u2011mucoadhesive MEAI solution. Using freshly isolated rabbit nasal mucosa, both formulations were applied to the tissue surface and allowed to interact with the mucosa before exposure to a simulated nasal electrolyte solution. The amount of formulation retained on the tissue was measured over a 30\u2011minute period to generate comparative residence time profiles.<\/p>\n

The intranasal MEAI formulation consistently maintained a greater proportion of its initially adhered dose throughout the entire evaluation period, demonstrating a clear retention advantage over the reference solution.<\/p>\n

These results highlight the contribution of the mucoadhesive polymer system incorporated into the intranasal MEAI formulation and provide further validation of Clearmind\u2019s nasal drug\u2011delivery platform, which is engineered to increase formulation residence at mucosal surfaces and enhance overall delivery performance.<\/p>\n

Extended residence time within the nasal cavity is widely recognized as a key factor in effective intranasal drug administration, as prolonged contact with the nasal mucosa increases the opportunity for absorption and may improve therapeutic efficiency. The observed retention profile suggests that Clearmind\u2019s intranasal MEAI formulation may offer meaningful advantages over conventional non\u2011mucoadhesive approaches.<\/p>\n

\n About Clearmind Medicine Inc.<\/b>\n <\/p>\n

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.<\/p>\n

The Company\u2019s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.<\/p>\n

Shares of Clearmind are listed for trading on Nasdaq under the symbol \u201cCMND.\u201d<\/p>\n

For further information, visit: https:\/\/www.clearmindmedicine.com<\/a>\u00a0or contact:<\/p>\n

Investor Relations<\/p>\n

\n invest@clearmindmedicine.com<\/a>\n <\/p>\n

\n www.Clearmindmedicine.com<\/a>\n <\/p>\n

\n Forward-Looking Statements:<\/b>\n <\/p>\n

This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cestimates\u201d and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential of MEAI, the ability to improve the residence time of MEAI within the nasal cavity, potentially increasing the opportunity for absorption, the company\u2019s intention to seek additional patents for its compounds whenever warranted and that it will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Forward-looking statements are not historical facts, and are based upon management\u2019s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management\u2019s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company\u2019s reports filed from time to time with the Securities and Exchange Commission (\u201cSEC\u201d), including, but not limited to, the risks detailed in the Company\u2019s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering non\u2011hallucinogenic neuroplastogen\u2011derived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, announced today compelling ex vivo mucoadhesion results for its intranasal formulation of MEAI (5\u2011Methoxy\u20112\u2011aminoindane). Leveraging a nasal drug\u2011delivery system, the new formulation demonstrated markedly improved nasal residence characteristics compared with a standard MEAI solution. Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential. These results reinforce Clearmind\u2019s strategy of developing differentiated, next\u2011generation treatments for AUD and other high\u2011need indications. The study forms a core component of Clearmind\u2019s intranasal MEAI development program, designed to overcome the limitations of rapid mucociliary clearance and deliver more consistent, effective … <\/p>\n

Continue reading “Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-982324","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nClearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering non\u2011hallucinogenic neuroplastogen\u2011derived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, announced today compelling ex vivo mucoadhesion results for its intranasal formulation of MEAI (5\u2011Methoxy\u20112\u2011aminoindane). Leveraging a nasal drug\u2011delivery system, the new formulation demonstrated markedly improved nasal residence characteristics compared with a standard MEAI solution. Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential. These results reinforce Clearmind\u2019s strategy of developing differentiated, next\u2011generation treatments for AUD and other high\u2011need indications. The study forms a core component of Clearmind\u2019s intranasal MEAI development program, designed to overcome the limitations of rapid mucociliary clearance and deliver more consistent, effective … Continue reading "Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T13:33:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzQxMCM3NzA5NjQxIzUwMDA4NjkzNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI\",\"datePublished\":\"2026-07-16T13:33:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\\\/\"},\"wordCount\":925,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MzQxMCM3NzA5NjQxIzUwMDA4NjkzNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\\\/\",\"name\":\"Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MzQxMCM3NzA5NjQxIzUwMDA4NjkzNA==\",\"datePublished\":\"2026-07-16T13:33:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MzQxMCM3NzA5NjQxIzUwMDA4NjkzNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MzQxMCM3NzA5NjQxIzUwMDA4NjkzNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/","og_locale":"en_US","og_type":"article","og_title":"Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI - Market Newsdesk","og_description":"Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering non\u2011hallucinogenic neuroplastogen\u2011derived treatments for Alcohol Use Disorder (AUD), addiction, and weight management, announced today compelling ex vivo mucoadhesion results for its intranasal formulation of MEAI (5\u2011Methoxy\u20112\u2011aminoindane). Leveraging a nasal drug\u2011delivery system, the new formulation demonstrated markedly improved nasal residence characteristics compared with a standard MEAI solution. Enhanced nasal retention is a critical step toward maximizing MEAI absorption and therapeutic potential. These results reinforce Clearmind\u2019s strategy of developing differentiated, next\u2011generation treatments for AUD and other high\u2011need indications. The study forms a core component of Clearmind\u2019s intranasal MEAI development program, designed to overcome the limitations of rapid mucociliary clearance and deliver more consistent, effective … Continue reading \"Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-16T13:33:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzQxMCM3NzA5NjQxIzUwMDA4NjkzNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI","datePublished":"2026-07-16T13:33:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/"},"wordCount":925,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzQxMCM3NzA5NjQxIzUwMDA4NjkzNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/","name":"Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzQxMCM3NzA5NjQxIzUwMDA4NjkzNA==","datePublished":"2026-07-16T13:33:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzQxMCM3NzA5NjQxIzUwMDA4NjkzNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MzQxMCM3NzA5NjQxIzUwMDA4NjkzNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-medicine-reports-positive-retention-results-for-intranasal-formulation-of-its-psychedelic-based-neuroplastogen-meai\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/982324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=982324"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/982324\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=982324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=982324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=982324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}